Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Comparing Biventricular Pacing and Left Bundle Branch Pacing for Heart Failure

Official title: Randomized Study of Integrated Evaluation of Conventional Biventricular and Left Bundle Branch Pacing Therapy Effect on Left Ventricular Remodeling and Clinical Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Run by Tomsk National Research Medical Center of the Russian Academy of Sciences · NCT05769036 · Data updated 2026-11-12

This study is testing whether a new way of pacing the heart can help people with heart failure feel better and improve their heart function compared to the standard method.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment60 (estimated)
SponsorTomsk National Research Medical Center of the Russian Academy of Sciences
Academic / other
Locations1 site (Tomsk)
StatusRecruiting
StartedOctober 1, 2023
Main results expectedJune 1, 2028
Study endsSeptember 1, 2028
Registry record updatedSeptember 10, 2025
Trial IDNCT05769036 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 to 80 with symptomatic heart failure and specific heart function criteria.

Probably not a fit

Patients with heart failure who do not meet the inclusion criteria, such as those with certain arrhythmias or higher left ventricular ejection fractions, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to compare the outcomes of conventional biventricular pacing with left bundle branch pacing in patients suffering from heart failure. It focuses on individuals with ischemic and non-ischemic cardiomyopathy who have reduced left ventricular function and left bundle branch block. The study will involve the implantation of cardioverter-defibrillators equipped with either pacing method to assess their effectiveness in improving heart function and patient quality of life. The trial will monitor various clinical parameters and patient responses over time to determine which pacing strategy yields better results.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for heart failure patients, enhancing their quality of life and reducing hospitalizations.

How similar studies have gone: Other studies have shown promising results with similar pacing approaches, suggesting potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

1. The patient is willing and able to comply with the protocol and has provided written informed consent;
2. Male or female patients aged 18 to 80 years;
3. Patients with ischemic or non-ischemic cardiomyopathy;
4. Symptomatic HF for at least 3 months prior to enrollment in the study;
5. New York Heart Association (NYHA) functional class HF ≥ II;
6. Patients with HF in sinus rhythm (SR) with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with LBBB morphology;
7. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration 130-149 ms with LBBB morphology;
8. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with non-LBBB morphology;
9. Patients with symptomatic persistent or permanent atrial fibrillation, HF with LVEF \< 40% (measured in the last 6 weeks prior to enrollment) and an uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration);
10. Patients with HF, LVEF \< 40% (measured in the last 6 weeks prior to enrollment) and indications for continuous ventricular pacing due to bradycardia;
11. Patients who have received a conventional pacemaker or an implanted cardioverter-defibrillator and who subsequently develop symptomatic HF with LVEF \< 40% (measured in the last 6 weeks prior to enrollment) despite optimal medical therapy, and who have a significant proportion of right ventricle pacing;
12. Optimal HF medical therapy.

Exclusion criteria:

1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;
2. Acute myocardial infarction within 3 months prior to enrollment;
3. Acute coronary syndrome;
4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);
5. Patients listed for heart transplant;
6. Patients with implanted cardiac assist device;
7. Acute myocarditis;
8. Infiltrative myocardial disease;
9. Hypertrophic cardiomyopathy;
10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;
11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;
12. Mental or physical inability to participate in the study;
13. Patients unable or unwilling to cooperate within the study protocol;
14. Patients with rheumatic heart disease;
15. Mechanic tricuspid valve patients;
16. Patients with any serious medical condition that could interfere with this study;
17. Enrollment in another investigational drug or device study;
18. Patients not available for follow-up;
19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml/min/1.73 m2);
20. Life expectancy ≤ 12 months;
21. Participation in another telemonitoring concept.

Where it's running

  • Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
    Tomsk, Russia
    Recruiting

Study contacts

  • Principal investigator: Tariel A Atabekov, Ph.D. — Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
  • Study coordinator: Tariel A Atabekov, Ph.D.
  • Email: kgma1011@mail.ru
  • Phone: +79528002625

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.